Immune checkpoint inhibitors such as anti-PD-L1 (atezolizumab), anti-PD-1 (nivolumab and pembrolizumab) and anti-CTLA-4 (ipilimumab) are currently not widely used in the treatment of GC [17]. This evidence concerns the gene CTLA4 and gastric cancer.